← Back to Clinical Trials
Recruiting NCT06138080

NCT06138080 Diagnosing Vesicoureteric Reflux in Children by Direct Isotope Cystography and Contrast Enhanced Voiding Ultrasonography

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06138080
Status Recruiting
Phase
Sponsor Turku University Hospital
Condition VUR - Vesicoureteric Reflux
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2022-05-15
Primary Completion 2030-05-15

Eligibility & Interventions

Sex All sexes
Min Age 0 Years
Max Age 6 Years
Study Type INTERVENTIONAL
Interventions
Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2022-05-15 with a primary completion date of 2030-05-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to examine the applicability of contrast enhanced voiding ultrasonography in diagnosing vesicoureteral reflux (VUR) in pediatric patients compared to direct isotope cystography. The aim of the study is to find a modality allowing the accurate diagnosis of VUR and the classification of the degree of VUR with the least possible harm from the examinations. The investigators recruit 100 under 6 years old patients who have had at least 2 culture positive urinary tract infections. Exluding criteria are abnormal bladder function and posterior uretral valves. The investigators perform direct isotope cystography and contrast enhanced voiding urosonography during the same day to diagnose and grade VUR. The investigators use standardized volume and speed of bladder filling. The examinations are done by a radiologist and an isotope specialist and they are blinded to the result of the other examination.

Eligibility Criteria

Inclusion Criteria: * under 6 years old patients who have had at least 2 culture positive urinary tract infections Exclusion Criteria: * abnormal bladder function * posterior uretral valves

Contact & Investigator

Central Contact

Hanna-Reeta Viljamaa

✉ hanna-reeta.viljamaa@tyks.fi

📞 +35823130000

Frequently Asked Questions

Who can join the NCT06138080 clinical trial?

This trial is open to participants of all sexes, aged 0 Years or older, up to 6 Years, studying VUR - Vesicoureteric Reflux. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06138080 currently recruiting?

Yes, NCT06138080 is actively recruiting participants. Contact the research team at hanna-reeta.viljamaa@tyks.fi for enrollment information.

Where is the NCT06138080 trial being conducted?

This trial is being conducted at Turku, Finland.

Who is sponsoring the NCT06138080 clinical trial?

NCT06138080 is sponsored by Turku University Hospital. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology